Diane Lynne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5120649/publications.pdf

Version: 2024-02-01

35 papers	3,479 citations	201385 27 h-index	344852 36 g-index
36 all docs	36 docs citations	36 times ranked	5896 citing authors

#	Article	IF	Citations
1	Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8644-8649.	3.3	523
2	Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 979-984.	3.3	305
3	The miR-106b-25 cluster targets Smad7, activates TGF-Î² signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene, 2012, 31, 5162-5171.	2.6	276
4	Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncology, 2013, 49, 287-292.	0.8	211
5	CCAAT/enhancer binding protein Â is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6462-6467.	3.3	169
6	Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genetics, 2005, 37, 265-274.	9.4	166
7	Combinatorial Analysis of Transcription Factor Partners Reveals Recruitment of c-MYC to Estrogen Receptor-Î± Responsive Promoters. Molecular Cell, 2006, 21, 393-404.	4.5	165
8	Regulation of DNA methylation of Rasgrf1. Nature Genetics, 2002, 30, 92-96.	9.4	155
9	Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 982-987.	3.3	150
10	Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. International Journal of Cancer, 2003, 104, 603-610.	2.3	146
11	ChIP-chip Comes of Age for Genome-wide Functional Analysis: Figure 1.. Cancer Research, 2006, 66, 6899-6902.	0.4	136
12	20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes and Cancer, 2006, 45, 957-966.	1.5	101
13	EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene, 2006, 25, 769-780.	2.6	91
14	Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein Î± Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2007, 67, 4657-4664.	0.4	76
15	Crosstalk between Chemokine Receptor CXCR4 and Cannabinoid Receptor CB2 in Modulating Breast Cancer Growth and Invasion. PLoS ONE, 2011, 6, e23901.	1.1	75
16	microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase CE›. Oncogene, 2012, 31, 4045-4053.	2.6	74
17	Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene, 2014, 33, 1037-1046.	2.6	69
18	Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis, 2011, 32, 1467-1473.	1.3	64

#	Article	IF	Citations
19	Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood, 2005, 105, 1310-1318.	0.6	62
20	Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. Journal of Clinical Oncology, 2006, 24, 1712-1719.	0.8	60
21	Unraveling the epigenetic code of cancer for therapy. Trends in Genetics, 2007, 23, 449-456.	2.9	59
22	DNA copy number gains in head and neck squamous cell carcinoma. Oncogene, 2006, 25, 1424-1433.	2.6	49
23	Epigenetic regulation of beta2-adrenergic receptor expression in TH1 and TH2 cells. Brain, Behavior, and Immunity, 2011, 25, 408-415.	2.0	46
24	Testing a Model of Nontraditional Career Choice Goals With Mexican American Adolescent Men. Journal of Career Assessment, 2006, 14, 214-234.	1.4	39
25	Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing. BMC Genomics, 2007, 8, 131.	1.2	38
26	Restriction Landmark Genomic Scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics, 2007, 8, 446.	1.2	37
27	Dying endothelial cells stimulate proliferation of malignant glioma cells via a caspase 3-mediated pathway. Oncology Letters, 2013, 5, 1615-1620.	0.8	30
28	An AscI Boundary Library for the Studies of Genetic and Epigenetic Alterations in CpG Islands. Genome Research, 2002, 12, 1591-1598.	2.4	24
29	CR16, a novel proline-rich protein expressed in rat brain neurons, binds to SH3 domains and is a MAP kinase substrate. Journal of Molecular Neuroscience, 1996, 7, 203-215.	1.1	22
30	Identification of Cyclic AMP Response Element in the Human Renin Gene. Biochemical and Biophysical Research Communications, 1994, 200, 320-329.	1.0	21
31	Metabolism of 17?-Estradiol and the Adrenal-Derived Estrogen 5-Androstene-3?, 17?-Diol (Hermaphrodiol) in Human Mammary Cell Lines. Annals of the New York Academy of Sciences, 1990, 595, 93-105.	1.8	12
32	Natural killer cell cytolytic activity is necessary forin vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. International Journal of Cancer, 2003, 106, 528-533.	2.3	12
33	Fluorescence-Guided Brain Tumor Surgery. World Neurosurgery, 2012, 78, 559-564.	0.7	8
34	Human renin 5â€²-flanking DMA to nucleotide -2750. DNA Sequence, 1995, 5, 319-321.	0.7	4
35	DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC). Current Genomics, 2004, 5, 489-498.	0.7	1